Coming Soon – October 2019

More than two dozen antiepileptic drugs (AEDs) are available in the United States, yet approximately one-third of epilepsy patients are refractory to AED treatment. Opportunity in this arena has spurred the development of a range of new AEDs targeting drug-resistant epilepsy, particularly highly refractory orphan pediatric subpopulations such as Lennox-Gastaut syndrome, Dravet syndrome, and patients with acute repetitive seizures; nine AEDs have been recently approved or are in late-phase development for these and other clinical niches. Understanding how prescribers perceive and plan to incorporate new brands is critical for developers facing a complicated, highly generic, and increasingly competitive market.

Questions Answered

  • How do neurologists perceive the clinical profiles of recently launched and emerging brands?
  • How do neurologists currently prescribe or plan to prescribe new brands? How will they be incorporated into the treatment algorithm?
  • What are the top reasons why some neurologists do not prescribe or would refrain from prescribing recently launched or emerging brands?
  • How will the availability of new brands impact current prescribing for the broad epilepsy population, as well as for niche epilepsy subpopulations?

Geographies: United States

Primary research: Survey of 100 neurologists

Key drugs covered: Epidiolex, Fintepla, cenobamate, padsevonil, Libervant, Nayzilam, Valtoco

Key insights provided:

  • Willingness to prescribe key emerging therapies
  • Current/anticipated use of newly launched and emerging therapies and their impact on current treatment
  • Obstacles to uptake of newly launched and emerging therapies
  • Potential uptake of emerging therapies in key epilepsy syndromes

Product Description

DRG’s Special Topics reports use quantitative primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report on epilepsy will help developers gauge the competitiveness of their late-phase pipeline candidates and design messages to support or defend their market position.

Table of contents

  • Detailed, Expanded Analysis (US): Special Topics
    • Coming Soon
      • Coming Soon

Author(s): Bethany Christmann, PhD

Bethany Christmann, has been with DRG since 2015, and is a Senior Business Insights Analyst with the Central Nervous System/Ophthalmology team. In this role, she covers the neurology space, specializing in Parkinson’s disease and epilepsy; she provides expert insight and authors primary market research and forecasting content focused on these and other neurology indications. Prior to joining DRG, Bethany earned her in neuroscience from Brandeis University, where she studied the cellular interactions involved in memory consolidation and their link to sleep behavior.

Related Reports

Epilepsy | Landscape & Forecast | Disease Landscape & Forecast

Epilepsy, which afflicts approximately 4.7 million people in the G7, according to DRG epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient&rsqu...

View Details

Epilepsy | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Partial Onset (US)

DRG epidemiologists estimate that 60% of epilepsy patients experience partial-onset seizures (POS), which...

View Details

Epilepsy | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Generalized Onset Seizures (US)

DRG epidemiologists estimate that 40% of epilepsy patients experience generalized-onset seizures (GOS...

View Details

Epilepsy | Unmet Need | Detailed, Expanded Analysis : Childhood Absence Epilepsy : US/EU

Childhood absence epilepsy (CAE) is characterized by frequent and brief absence seizures in children aged 4-12 and is diagnosed in approximately 10...

View Details